Ignite Creation Date:
2024-05-06 @ 6:42 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05750758
Status:
COMPLETED
Last Update Posted:
2024-02-23
First Post:
2023-02-20
Brief Title:
Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
Sponsor:
Henan Institute of Cardiovascular Epidemiology
Organization:
Henan Institute of Cardiovascular Epidemiology
Study Overview
Official Title:
A Randomized Controlled Trial of Rivaroxaban Combined With Dual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Alone 1 Month After Drug-coated Balloon Angioplasty in Patients With Acute Coronary Syndrome Without High Bleeding Risk
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The target population of this interventional study was ACS patients with drug-coated balloons The main discussion 11 months of rivaroxaban combined with dual antiplatelet therapy compared with dual antiplatelet therapy alone late lumen loss at 6 months 2 To determine the safety of the regimen with bleeding events as the end point Subjects were randomly assigned to two groups one receiving routine DAPT for six months and one receiving DAPT plus one month of rivaroxaban 25 mg bid
Detailed Description:
Drug-coated balloon DCB is to apply anti-intimal hyperplasia drugs to the surface of the balloon When the balloon reaches the diseased blood vessel and is stretched and expanded it contacts the intima of the blood vessel wall By tearing the intima of the blood vessel and pressing the transfer drug is quickly released to the intima of the blood vessel thereby preventing restenosis after vascular intervention Pretreatment is a key step in the use of drug balloons in situ macroangiopathy At present it is required that the residual stenosis of the lesion during pretreatment is 30 and there is no distal blood flow restrictive dissection and hematoma The relationship between dissection hematoma and residual stenosis is difficult to deal with Some small dissections are beneficial to the absorption of DCB anti-proliferative drugs by the vascular wall The larger dissection may cause the thrombus to persist in the vascular wall resulting in late lumen loss after organization Rivaroxaban is a new oral anticoagulant which is gradually used in the treatment of coronary heart disease At present there is no clinical study on the prognosis of vascular dissection in DCB Based on the above research background we designed the following trial aimed to study in ACS population vascular lumen access hemorrhagic events as the end point try to clear 1 month rivaroxaban combined with dual antiplatelet therapy compared with single dual antiplatelet therapy effect
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None